drugset / Trial / NCT07638631
Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with unresectable locally advanced gastric cancer who had not received systemic treatment.
Timeline
- Start
- 2026-06-15
- Primary completion
- 2028-12-31
- Completion
- 2030-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 600 mg/m2 | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Oxaliplatin | Small molecule | 78 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |